MedTrace Logo

Indacaterol in Heart Failure Patients: Any Role on Lung Fluid Regulation

NCT02598505 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2020-01-27

No results posted yet for this study

Summary

The purposes of this study are:

1. To confirm safety of Indacaterol in stable Heart Failure.
2. To determine whether beta 2 alveolar receptor stimulation by Indacaterol is able to ameliorate lung diffusion in heart Failure patients treated with beta blockers.
3. To compare the effects of Indacaterol in patients treated with a non-selective beta blocker (Carvedilol) and a beta 1-selective beta blocker (Bisoprolol).

Conditions

Interventions

DRUG

Indacaterol

DRUG

Placebo

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Centro Cardiologico Monzino

    lead OTHER

Principal Investigators

  • Piergiuseppe Agostoni, MD · Centro Cardiologico Monzino

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2016-11-30
Completion
2016-11-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02598505 on ClinicalTrials.gov